NEKTAR THERAPEUTICS (NKTR)
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business